Invagen Pharmaceutical receives USFDA approval for Pregabalin Capsules

InvaGen Pharmaceuticals, Inc. (InvaGen), a wholly-owned subsidiary of Cipla announced the receipt of final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration (US FDA).

InvaGen's Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg is AB-rated generic therapeutic equivalent version of Pfizer's Lyrica. Pregabalin capsules are indicated for:

Management of neuropathic pain associated with diabetic peripheral neuropathy